arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Arcus Biosciences, Inc.

RCUS
$28.70 ▲ +0.30 (+1.06%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Arcus Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.6B
Dividend Yield
Revenue Growth -39.3%
Op. Margin None
ROIC -21.5%
FCF / Share $-1.10
Trailing P/E
Price / Book 6.9x
FCF Yield
Debt / Equity 0.19
info Valuation on last close. End-of-day price, Aug 7, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.00M
↓ -39.3%
Net Income Profit after all expenses
$-128.00M
↓ -14.3%
Operating Margin Operating profit as % of sales
-345.5%
↓ -6809.1% 1th
FCF / Share Free cash flow per share
$-1.10
↑ +18.6%
Long-Term Debt Long-term obligations
$100.00M
↑ +1.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
15
Financial Health
47
Cash Quality
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 39 quarters